<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Pharmacol Toxicol</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Pharmacol Toxicol</journal-id>
      <journal-title-group>
        <journal-title>BMC Pharmacology &amp; Toxicology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2050-6511</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27098382</article-id>
      <article-id pub-id-type="pmc">4839135</article-id>
      <article-id pub-id-type="publisher-id">60</article-id>
      <article-id pub-id-type="doi">10.1186/s40360-016-0060-2</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Talotta</surname>
            <given-names>Rossella</given-names>
          </name>
          <address>
            <phone>+390239043351</phone>
            <email>talotta1@virgilio.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Atzeni</surname>
            <given-names>Fabiola</given-names>
          </name>
          <address>
            <phone>+390239043351</phone>
            <email>atzeni.fabiola@hsacco.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sarzi Puttini</surname>
            <given-names>Piercarlo</given-names>
          </name>
          <address>
            <phone>+390239043351</phone>
            <email>sarzi.piercarlo@hsacco.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1">Rheumatology Unit, University Hospital &#x201C;Luigi Sacco&#x201D;, Via GB Grassi 74, 20157 Milan, Italy </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>21</day>
        <month>4</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>21</day>
        <month>4</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2016</year>
      </pub-date>
      <volume>17</volume>
      <elocation-id>17</elocation-id>
      <history>
        <date date-type="received">
          <day>23</day>
          <month>12</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>23</day>
          <month>3</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Talotta et al. 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Abatacept (ABA) is a fusion receptor protein containing the CTLA-4 domain that prevents the activation of na&#xEF;ve T cells by binding the CD80 and CD86 molecules expressed on the surface of dendritic cells, indicated for the treatment of moderate to severe rheumatoid arthritis (RA). There is still little evidence concerning the safety of ABA in RA patients with positive serology for hepatitis virus B (HBV) infection.</p>
        </sec>
        <sec>
          <title>Case Presentation</title>
          <p>We report the case of a&#xA0;HBV infection reactivation in an ABA-treated male RA patient. The patient (caucasian race, 66-year-old) was diagnosed with RA in Novembre 2010 and in December 2010 he started a treatment with prednisone plus subcutaneous methotrexate. In October 2011, an anti-TNF agent (golimumab) was added but soon discontinued due to an adverse event. At baseline, screening for HBV markers showed a positivity for HBcAb and HBeAb IgG, being HBsAg, HBsAb, HBcAb IgM, HBeAg and HBV DNA negative. Serum amino-transferase (AST and ALT) levels were within the normal range. In January 2012 he was swapped to intravenous treatment with ABA 750&#xA0;mg/month, that allowed the achievement of a good clinical response and the permanent discontinuation of corticosteroids. In November 2013, laboratory reports showed that he was positive for HBcAb but negative for the remaining HBV markers, and had a slightly increased AST level and, in December 2013, he became HBV DNA positive (326&#xA0;IU/mL). In January 2014, his HBV DNA levels had further increased and ABA was stopped while maintaining MTX. He started lamivudine 100&#xA0;mg/day in January 2014. After 1&#xA0;month of lamivudine, his HBV DNA levels became undetectable (&lt;10&#xA0;IU/mL) and liver function was normal although RA had been reactivated (DAS28 5.53). Treatment with ABA was therefore resumed with the achievement of a good response after 6&#xA0;months. The patient is currently being treated with lamivudine 100&#xA0;mg/day, i.v. ABA 750&#xA0;mg/month, and MTX 15&#xA0;mg/week, with a good response (DAS28 2.27 in October 2015), and constantly monitored without any further evidence of HBV infection reactivation.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>Although there are still few reports in literature, we suggest caution in HBV- occult carriers RA patients undergoing a treatment with abatacept.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Abatacept</kwd>
        <kwd>Hepatitis B</kwd>
        <kwd>Reactivation</kwd>
        <kwd>Rheumatoid arthritis</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>The treatment of rheumatoid arthritis (RA) includes many biologic drugs blocking different steps of the inflammatory cascade. Abatacept (ABA) is a fusion receptor protein containing the CTLA-4 domain that prevents the activation of na&#xEF;ve T-cells by binding CD80 and CD86 expressed on the surface of dendritic cells [<xref ref-type="bibr" rid="CR1">1</xref>]. Abatacept, with or without methotrexate (MTX), is approved for treating moderate to severe RA in patients refractory to previous disease modifying anti-rheumatic drugs (DMARDs) and anti- TNF drugs.</p>
      <p>Evidences show the safety of ABA in RA patients with positive serology for hepatitis virus (HBV) infection [<xref ref-type="bibr" rid="CR2">2</xref>], and there are few reports of HBV reactivation. We observed a case of HBV infection reactivation in a Caucasian male patient affected by RA treated with ABA.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>The patient, 66&#xA0;years old, was diagnosed with RA in November 2010 according to the new European League Against Rheumatisms (EULAR)/American College of Rheumatology (ACR) 2010 criteria [<xref ref-type="bibr" rid="CR3">3</xref>]. At baseline clinical examination showed 23 swollen joints and 26 tender joints, increased values of Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP) and of Rheumatoid Factor (RF) (15&#xA0;mg/L) and anti-citrullinated peptides antibodies (ACPA). Complete blood count, serum amino-transferases and creatinine were within the range of normality. X-rays of both hands and feet showed juxta articular osteoporosis but no bone erosions.</p>
      <p>In December 2010 he started a treatment with prednisone 5&#xA0;mg/day plus subcutaneous MTX 10&#xA0;mg/week, which was increased up to 15&#xA0;mg/week in February 2011. Due to persistent disease activity (DAS28 = 4.16), in October 2011 the patient was considered candidate to a biologic agent according to the Italian guidelines and therefore a screening for opportunistic infections was required [<xref ref-type="bibr" rid="CR4">4</xref>]. Tuberculosis screening assessed by interferon-gamma release assay (IGRA) proved negative. Thorax X-rays showed no pleural or pulmonary lesion. Hepatitis screening showed a positivity for HBcAb IgG and HBeAb IgG, while HBsAg, HBsAb, HBcAb IgM, HBeAg and HCV-Ab were negative. HBV DNA was negative (&lt;20 IU/mL), AST and ALT value were within the normal range (20 and 27 IU/L respectively). In November 2011 a therapy with golimumab 50&#xA0;mg every month was started, but it was permanently discontinued after three weeks due to adverse effects (cough and tachycardia). In January 2012 the patient was swapped to a treatment with abatacept (ABA) e.v. 750&#xA0;mg&#xA0;monthly. At baseline DAS28 was 4.85; CRP value was 19&#xA0;mg/L (normal values&#x2009;&lt;&#x2009;1&#xA0;mg/L), ESR 21&#xA0;mm (normal values&#x2009;&lt;&#x2009;27&#xA0;mm), AST 18 IU/L (normal values&#x2009;&lt;&#x2009;40 IU/L) and ALT 30 IU/L (normal values&#x2009;&lt;&#x2009;40 IU/L).</p>
      <p>HBV DNA, AST and ALT were evaluated every three months, and remained within the normal range. The response to ABA therapy was good with DAS28 achieving the score of 2.31 after 3&#xA0;months. The patient maintained a clinical remission at the follow-up visits&#xA0;despite the tapering and the definitive discontinuation of corticosteroids.</p>
      <p>However, in November 2013 laboratory reports showed a positivity in HBcAb with a negativity in the remaining HBV serologic markers (HBsAg, HBcAb, HBeAg, HBeAb, HCV-Ab) and a mild increase in the value of AST (41 IU/L). Furthermore, in December 2013 HBV DNA turned positive with a level of 326 IU/mL (normal range &lt;20 IU/mL). In January 2014, a subsequent control of HBV-DNA revealed a further increase up to 1416 IU/mL. ABA was then stopped maintaining MTX, and the patient referred to a hepatologist. A liver examination by means of abdominal ultrasound was done, resulting into normal findings. However, since January 2014 a treatment with lamivudine 100&#xA0;mg/day was started.</p>
      <p>After 1&#xA0;month of lamivudine, HBV DNA became undetectable (&lt;10&#xA0;IU/mL) and liver functionality was normal (AST 29 IU/L, ALT 38 IU/L); on the contrary CRP values were greatly increased (42.4&#xA0;mg/L) and RA reactivated (DAS28 = 5.53); therefore the treatment with ABA was reintroduced. The patient experimented a rapid benefit on the rheumatic symptoms reaching a good EULAR response after 3&#xA0;months. In April 2014 liver functionality was good (AST 29 IU/L, ALT 31 IU/L), HBV-DNA was &lt;10 IU/mL and an assessment through Fibroscan showed an index of stiffness of 3.9 kPA.</p>
      <p>The patient is currently treated with lamivudine 100&#xA0;mg/day, i.v. abatacept 750&#xA0;mg&#xA0;every month and MTX 15&#xA0;mg/week with a good response (DAS28 = 2.27 in October 2015). Figure <xref rid="Fig1" ref-type="fig">1</xref> illustrates the time-course of DAS28, AST, ALT and HBV DNA levels.<fig id="Fig1"><label>Fig. 1</label><caption><p>Time-course of DAS28, AST, ALT and HBV DNA levels. DAS28: Disease Activity Score (28 Joints); AST: ASpartate aminotransferase; ALT: ALanine aminotransferase; HBV DNA: Hepatitis B Virus DNA</p></caption><graphic xlink:href="40360_2016_60_Fig1_HTML" id="MO1"/></fig></p>
    </sec>
    <sec id="Sec3">
      <title>Conclusions</title>
      <p>The association between ABA and HBV infection is still unclear. Germanidis et al. [<xref ref-type="bibr" rid="CR5">5</xref>] reported the case of a elderly RA woman who developed an active HBV hepatitis after 1 year of treatment with ABA. The patient was concomitantly treated with prednisone 10&#xA0;mg/day and leflunomide 20&#xA0;mg/day, perhaps favouring the viral reactivation. Our patient did not need concomitant treatment with prednisone because the RA disease activity was persistently low under ABA treatment (DAS28&#x2009;&lt;&#x2009;2.6).</p>
      <p>Other authors reported a case of HBV reactivation in an occult carrier receiving ABA as first biologic line for RA [<xref ref-type="bibr" rid="CR6">6</xref>]. In this case a treatment with tenofovir 300&#xA0;mg/day was started and ABA was permanently discontinued. A recent &#x201C;real life&#x201D; Italian study was carried on 72 RA patients with concomitant HBV infection, treated with ABA plus steroids and conventional Disease Modifying Anti-Rheumatic Drugs (DMARDs). Among them, 21 were occult carriers who received prophylaxis with lamivudine only in 9 cases. No viral reactivation was detected in a 24&#xA0;months follow-up period, underlining a safe profile of ABA during HBV infection, also without applying antiviral prophylaxis [<xref ref-type="bibr" rid="CR7">7</xref>]. However, in our experience, a treatment with a biologic agent inducing a peripheral tolerance could favour the progression of HBV infection in an occult carrier. The concomitant use of corticosteroids may represent an aggravating factor, whereas the use of methotrexate may be helpful in preventing the immune-mediated damage to HBV-infected hepatocytes [<xref ref-type="bibr" rid="CR8">8</xref>]. Therefore, HBV DNA and serum levels of AST and ALT should be periodically monitored in occult carriers. In case of HBV reactivation patients can be successfully treated with antiviral agents while continuing the treatment with ABA [<xref ref-type="bibr" rid="CR9">9</xref>]. In conclusion, reports remain still isolated in literature and, according to our experience, this is the first case of HBV reactivation under ABA in our cohort of RA patients (n.9) affected by occult HBV infection.</p>
    </sec>
    <sec id="Sec4">
      <title>Consent</title>
      <p>Written informed consent for publication of the clinical details was obtained from the patient. A copy of the consent form is available for review by the Editor of this journal.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>ABA</term>
          <def>
            <p>abatacept</p>
          </def>
        </def-item>
        <def-item>
          <term>ACPA</term>
          <def>
            <p>anti-citrullinated peptides antibodies</p>
          </def>
        </def-item>
        <def-item>
          <term>ACR</term>
          <def>
            <p>American College of Rheumatology</p>
          </def>
        </def-item>
        <def-item>
          <term>CRP</term>
          <def>
            <p>C-reactive protein</p>
          </def>
        </def-item>
        <def-item>
          <term>DAS28</term>
          <def>
            <p>disease activity score (28 Joint)</p>
          </def>
        </def-item>
        <def-item>
          <term>DMARDs</term>
          <def>
            <p>disease modifying anti-rheumatic drugs</p>
          </def>
        </def-item>
        <def-item>
          <term>ESR</term>
          <def>
            <p>erythrocyte sedimentation rate</p>
          </def>
        </def-item>
        <def-item>
          <term>EULAR</term>
          <def>
            <p>European League Against Rheumatisms</p>
          </def>
        </def-item>
        <def-item>
          <term>HBV</term>
          <def>
            <p>hepatitis B virus</p>
          </def>
        </def-item>
        <def-item>
          <term>IGRA</term>
          <def>
            <p>interferon-gamma release assay</p>
          </def>
        </def-item>
        <def-item>
          <term>MTX</term>
          <def>
            <p>methotrexate</p>
          </def>
        </def-item>
        <def-item>
          <term>RA</term>
          <def>
            <p>rheumatoid arthritis</p>
          </def>
        </def-item>
        <def-item>
          <term>RF</term>
          <def>
            <p>rheumatoid factor</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contribution</bold>
        </p>
        <p>RT conceived the study and drafted the manuscript. AF participated in the design of the study and drafted the manuscript. PCSP participated in the design and coordination of the study. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <p>We acknowledge all the physicians at Rheumatology Unit of the University Hospital "Luigi Sacco" who allowed us to have access to the patient's source documents.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vital</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Emery</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Abatacept in the treatment of rheumatoid arthritis</article-title>
          <source>Ther Clin Risk Manag</source>
          <year>2006</year>
          <volume>2</volume>
          <issue>4</issue>
          <fpage>365</fpage>
          <lpage>75</lpage>
          <pub-id pub-id-type="doi">10.2147/tcrm.2006.2.4.365</pub-id>
          <pub-id pub-id-type="pmid">18360649</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <mixed-citation publication-type="other">Padovan M, Lanciano E, Epis O, Mathieu A, Erba G, Ciani L, et al. Safety of Abatacept in rheumatoid arthritis with chronic hepatitis B virus infection. Abstract 356 ACR 2013.</mixed-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smolen</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Landew&#xE9;</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Breedveld</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>Dougados</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Emery</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gaujoux-Viala</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs</article-title>
          <source>Ann Rheum Dis</source>
          <year>2010</year>
          <volume>69</volume>
          <issue>6</issue>
          <fpage>964</fpage>
          <lpage>75</lpage>
          <pub-id pub-id-type="doi">10.1136/ard.2009.126532</pub-id>
          <pub-id pub-id-type="pmid">20444750</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Caporali</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Conti</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Alivernini</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Atzeni</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Seriolo</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Cutolo</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Italian Society for Rheumatology. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy</article-title>
          <source>Clin Exp Rheumatol</source>
          <year>2011</year>
          <volume>29</volume>
          <issue>3 Suppl 66</issue>
          <fpage>S7</fpage>
          <lpage>14</lpage>
          <pub-id pub-id-type="pmid">21906423</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Germanidis</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hytiroglou</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Zakalka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Settas</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept</article-title>
          <source>J Hepatol</source>
          <year>2012</year>
          <volume>56</volume>
          <issue>6</issue>
          <fpage>1420</fpage>
          <lpage>1</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jhep.2011.10.011</pub-id>
          <pub-id pub-id-type="pmid">22127282</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fanouriakis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vassilopoulos</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Repa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Boumpas</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Sidiropoulos</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection</article-title>
          <source>Rheumatology (Oxford)</source>
          <year>2014</year>
          <volume>53</volume>
          <issue>1</issue>
          <fpage>195</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1093/rheumatology/ket221</pub-id>
          <pub-id pub-id-type="pmid">23771951</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <mixed-citation publication-type="other">Padovan M, Filippini M, Tincani A, Lanciano E, Bruschi E, Epis O et al. Safety of abatacept in rheumatoid arthritis with serological evidence of past or present hepatitis B virus infection. Arthritis Care Res (Hoboken). 2015 Nov.</mixed-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>L&#xF3;pez-Serrano</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>de la Fuente</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Alonso</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>P&#xE9;rez-Calle</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Rodr&#xED;guez</surname>
              <given-names>CF</given-names>
            </name>
          </person-group>
          <article-title>Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy</article-title>
          <source>World J Hepatol</source>
          <year>2015</year>
          <volume>7</volume>
          <issue>3</issue>
          <fpage>539</fpage>
          <lpage>47</lpage>
          <pub-id pub-id-type="doi">10.4254/wjh.v7.i3.539</pub-id>
          <pub-id pub-id-type="pmid">25848477</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>GY</given-names>
            </name>
            <name>
              <surname>Prete</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Furst</surname>
              <given-names>DE</given-names>
            </name>
          </person-group>
          <article-title>Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B</article-title>
          <source>Arthritis Care Res (Hoboken)</source>
          <year>2012</year>
          <volume>64</volume>
          <issue>8</issue>
          <fpage>1265</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">22392695</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
